On Monday, March 25, 2013, AstraZeneca UK Ltd. announced an agreement with Actavis Inc. and Egis Pharmaceuticals PLC, ending patent litigation over the “blockbuster cholesterol-reducing drug Crestor®.” In the deal, Actavis and Egis agreed not to launch a generic version of Crestor® until May 2016. Finnegan represented AstraZeneca in this matter.
